T-DXd Consistently Better Than Second-Line Standard in HER2+ mBC
A subgroup analysis of a phase III study, presented at the virtual San Antonio Breast Cancer Symposium, found consistent outcome benefits for women with…
Browsing Tag
HER2
Merus présente une analyse actualisée du zenocutuzumab, du trastuzumab et de la vinorelbine chez des…
- Le critère d'évaluation principal du taux de bénéfice clinique à 24 semaines avec la combinaison triplet a été atteint - La combinaison triplet a montré une activité cliniquement significative après 3 lignes de thérapies anti-HER2 dont…
Merus Presents Updated Analysis of Zenocutuzumab, Trastuzumab, and Vinorelbine in Patients with…
- The primary endpoint of Clinical Benefit Rate at 24 weeks with the triplet combination was met - The triplet combination showed clinically meaningful activity after 3 lines of anti-HER2 therapies including T-DM1 - Validates the…
Zai Lab Announces Margetuximab Achieved Primary Objective in Bridging Study in Advanced HER2+ Breast…
-- Demonstrated efficacy and safety consistent with global SOPHIA study-- Company expects to file BLA in China in advanced HER2+ breast cancer by approximately year end 2021 SHANGHAI and SAN FRANCISCO, Oct. 05, 2021 (GLOBE NEWSWIRE) --…
‘Massive Improvement’ With Second-Line Enhertu in HER2+ Breast Cancer
The recently approved antibody-drug conjugate trastuzumab deruxtecan (T-DXd; Enhertu) was clearly more effective in treating metastatic HER2-positive breast…
Samsung Bioepis Announces Five-year Follow-up Results for ONTRUZANT® (trastuzumab) in Early or…
Five-year follow-up results show comparable cardiac safety profile and long-term efficacy between biosimilar ONTRUZANT® (trastuzumab) and reference medicine HERCEPTIN® i (trastuzumab) in early or locally advanced HER2 positive breast…
Polyphor Provides Update on the Phase III FORTRESS Study of Balixafortide in Patients With Advanced…
Co-primary endpoint of the study objective response rate (ORR) was not metThe board of directors is undergoing a strategic assessment regarding the future of the company ALLSCHWIL, Switzerland, June 28, 2021 (GLOBE NEWSWIRE) --…
Sorrento Announces Positive Results From Its License Partner, Kelun, on a Phase I Study of Safety…
A166 (ASCO Abstract #1024) is a third generation antibody drug conjugate (ADC) against HER2-positive breast cancer with Levena’s proprietary tubulin inhibitor Duo-5 toxin, cleavable linker and site-specific K-Lock™ conjugation chemistry.In…
Black Diamond Therapeutics Presents Phase 1 Pharmacokinetic, Safety, and Preliminary Efficacy Data…
Once-daily (QD) dose escalation completed; pharmacokinetic (PK) profile consistent with design principles and preclinical predictions Generally well-tolerated with medically manageable toxicities observed; safety profile compares…